Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of antidrug antibody combined with coronavirus bispecific antibody and preparation method and application thereof

A bispecific antibody, coronavirus technology, applied in the field of biomedicine, can solve problems such as loss, drug resistance escape, and vaccine protection decline, and achieve the effect of high binding affinity and specificity

Active Publication Date: 2022-04-19
SANYOU BIOPHARMACEUTICALS CO LTD +1
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Therefore, in response to the continuous mutation of the SARS-CoV-2 virus, as well as the possible drug resistance escape, vaccine protection decline or loss caused by the mutation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of antidrug antibody combined with coronavirus bispecific antibody and preparation method and application thereof
  • A kind of antidrug antibody combined with coronavirus bispecific antibody and preparation method and application thereof
  • A kind of antidrug antibody combined with coronavirus bispecific antibody and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0103] Example 1 Animal Immunization

[0104] The immunogenic protein used for antibody preparation is BsAb17 bispecific antibody, and the production and preparation process of BsAb17 bispecific antibody refers to patent application CN202011300574.2. The BsAb17 antibody was used as an immunogen to immunize Balb / C mice (Shanghai Lingchang Biotechnology Co., Ltd.). A total of 4 mice were immunized. The method of subcutaneous multi-point immunization was adopted, 50 μg subcutaneously each time, and immunized every two weeks. Once, a total of four immunizations. The titer of immunization was determined by ELISA after four immunizations. The test results showed that the immune titer reached 1:1458000, and the titer test results are shown in Table 1. At this time, 100 μg of BsAb17 was used for booster immunization, and the spleen was taken 2-3 days later. The sequence of BsAb17 is shown in Table 2.

[0105] Table 1 BsAb17 mice immune titer detection data

[0106]

[0107] Tab...

Embodiment 2

[0109] Example 2 Construction of immune library and antibody screening

[0110] 2.1 Phage display immune antibody library construction

[0111] The B lymphocytes in the spleen of the immunized mouse described in Example 1 were isolated, their RNA was extracted, and reverse-transcribed into cDNA by a reverse transcription kit (TaKaRa, 6210A). Design primers to amplify the coding sequences of the light chain variable region and the heavy chain variable region and the first constant region (CL and CH1) respectively, and connect the coding sequence of the M13 phage GIII protein at the 3' end of the coding sequence of CH1, Then cloned into a vector for phage display. Then, the vector was transformed into competent Escherichia coli SS320 cells (Lucigen, MC1061 F) by electroporation (Bio-Rad, MicroPulser). After recovery for 1 hour, the vector was spread on a 2-YT solid plate with ampicillin resistance. By serial dilution plating, the storage capacity of this immune library was det...

Embodiment 3

[0127] Example 3 Construction, expression and purification of antibodies

[0128] The 20 murine antibodies obtained in Example 2 were constructed as murine IgG1 subtype, and the amino acid sequences of the light and heavy chain variable regions of the antibodies are shown in Table 4-3 (SEQ ID NO: 1-34).

[0129] 3.1 Plasmid construction

[0130] From the candidate monoclonal strains obtained through screening, PCR amplification was performed to obtain DNA fragments encoding antibody heavy chain and light chain. By means of homologous recombination, the DNA fragments encoding each heavy chain and light chain were respectively constructed on the eukaryotic expression vector plasmid pcDNA3.4 (Invitrogen) containing the mouse IgG1 Fc fragment (SEQ ID NO: 35), and the complete Recombinant plasmids of heavy and light chain full-length genes, wherein the complete heavy chain contains the antibody heavy chain variable region, mouse CH1 fragment (SEQ IDNO: 36) and mouse IgG1 Fc fragme...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-drug antibody combined with a coronavirus bispecific antibody, a preparation method and application thereof. The anti-drug antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3, wherein each functional region See the present invention for details of the sequence. The anti-drug antibody screened by the invention has high binding affinity and specificity.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to an anti-drug antibody combined with a coronavirus bispecific antibody and its preparation method and application. Background technique [0002] Since the severe acute respiratory syndrome coronavirus (SARS-CoV) outbreak in 2002, coronavirus (CoV) has emerged as an RNA virus causing major public health concerns. Currently, the world is focusing on the 2019 novel coronavirus Coronavirus (SARS-CoV-2). This virus can be transmitted from person to person, and patients infected with this virus can present with severe viral pneumonia and respiratory disease. Since then, infection with SARS-CoV- 2 The number of cases has been increasing. [0003] Studies have shown that this type of coronavirus binds to the receptor angiotensin converting enzyme Ⅱ (also known as ACE2) on the host cell through the spike protein (Spike protein), and mediates the entry of the virus into the host cell...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/42C12N15/13
CPCC07K16/4216C07K16/005C07K2317/56C07K2317/565C07K2317/92
Inventor 刘婵娟郎国竣邵俊斌吕力琅张捷唐紧闫鑫甜王文蓉胡宇豪郑海亮闫闰
Owner SANYOU BIOPHARMACEUTICALS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com